Oncotelic partners with TechForce Robotics to develop AI-enhanced GMP robotics platform

Oncotelic Therapeutics, Inc.

Joint development, manufacturing, and licensing agreement signed March 31, 2026.
Combines Oncotelic's proprietary PDAOAI platform with TechForce's robotics hardware.
Platform targets GMP-compliant automated material handling, monitoring, and compliance workflows.
Financial terms not disclosed; revenue sharing and royalties to be negotiated in future agreement.
AI foreground IP owned by Oncotelic; jointly developed IP jointly owned.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Oncotelic Therapeutics, Inc. entered into Joint Development, Manufacturing, and Licensing Agreement with TechForce Robotics, Inc. valued at Joint development and manufacturing of AI-enabled, GMP-compliant robotic systems; non-exclusive lice (effective 2026-03-31).

Action: entry
Agreement: license
Counterparty: TechForce Robotics, Inc.
Value: Joint development and manufacturing of AI-enabled, GMP-compliant robotic systems; non-exclusive lice
Effective: 2026-03-31

Exact text from the filing

On March 31, 2026, Oncotelic Therapeutics, Inc. (the “Company”) entered into a Joint Development, Manufacturing, and Licensing Agreement (the “Agreement”) with TechForce Robotics, Inc. (“TechForce”), a Nevada corporation.

View on SEC.gov

76 material agreements filed in the last 30 days. Browse all material agreements →

Oncotelic Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-014831

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.